Freestone Grove Partners’s Axcelis ACLS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$233K Sell
1,228
-5,789
-82% -$859K ﹤0.01% 786
2026
Q1
$653K Buy
7,017
+28
+0.4% +$2.48K ﹤0.01% 555
2025
Q4
$561K Buy
+6,989
New +$585K ﹤0.01% 553

Other funds holding ACLS

Freestone Grove Partners's ACLS Position: Q2 2026 in Review

Freestone Grove Partners reduced its Axcelis (ACLS) stake by 82% in Q2 2026, selling an estimated $859K and leaving 1,228 shares worth $233K. The position accounts for ﹤0.01% of the portfolio, ranked #786.

Freestone Grove Partners first reported a position in ACLS in Q4 2025 and has held it in 3 quarters since. The position peaked at $653K in Q1 2026. 441 funds tracked by Wall St. Rank hold ACLS as of Q2 2026.

  • Freestone Grove Partners held 1,228 shares of Axcelis worth $233K as of Q2 2026.
  • Freestone Grove Partners sold 5,789 Axcelis shares in Q2 2026, an estimated $859K.
  • Axcelis made up ﹤0.01% of Freestone Grove Partners's portfolio in Q2 2026, its #786 holding.
  • Freestone Grove Partners first reported a position in Axcelis in Q4 2025 and has held it in 3 quarters since.
  • Freestone Grove Partners's Axcelis position peaked at $653K in Q1 2026.
  • 441 funds tracked by Wall St. Rank held Axcelis as of Q2 2026.

Based on Freestone Grove Partners's 13F filing for Q2 2026, filed 14 Aug 2026.